Palvella Therapeutics, Inc. (NASDAQ:PVLA – Get Free Report) Director George Jenkins sold 1,777 shares of the stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $150.14, for a total value of $266,798.78. Following the completion of the sale, the director owned 160,116 shares in the company, valued at approximately $24,039,816.24. The trade was a 1.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Palvella Therapeutics Trading Down 0.3%
PVLA traded down $0.47 on Tuesday, hitting $151.22. 215,632 shares of the company were exchanged, compared to its average volume of 186,628. The firm has a 50-day moving average price of $149.13 and a two-hundred day moving average price of $132.62. Palvella Therapeutics, Inc. has a twelve month low of $54.28 and a twelve month high of $161.38. The company has a market cap of $2.18 billion, a price-to-earnings ratio of -31.31 and a beta of -0.25.
Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). Equities analysts expect that Palvella Therapeutics, Inc. will post -6.36 EPS for the current year.
Wall Street Analysts Forecast Growth
Read Our Latest Report on PVLA
Institutional Trading of Palvella Therapeutics
A number of large investors have recently made changes to their positions in the company. Arizona State Retirement System grew its stake in Palvella Therapeutics by 30.9% during the 2nd quarter. Arizona State Retirement System now owns 2,765 shares of the company’s stock worth $423,000 after buying an additional 652 shares during the last quarter. Northwestern Mutual Wealth Management Co. purchased a new stake in Palvella Therapeutics in the second quarter valued at approximately $35,000. Penn Capital Management Company LLC purchased a new stake in Palvella Therapeutics in the second quarter valued at approximately $841,000. Hsbc Holdings PLC acquired a new stake in shares of Palvella Therapeutics in the second quarter valued at approximately $7,641,000. Finally, Wellington Management Group LLP boosted its holdings in shares of Palvella Therapeutics by 4.6% in the second quarter. Wellington Management Group LLP now owns 35,594 shares of the company’s stock valued at $5,439,000 after acquiring an additional 1,554 shares during the period. 40.11% of the stock is owned by institutional investors and hedge funds.
Palvella Therapeutics Company Profile
Palvella Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with rare genetic and dermatologic diseases. The company uses its proprietary QTORIN platform to formulate and deliver medicines locally to affected tissues, with the goal of improving treatment effectiveness while limiting systemic exposure.
Palvella’s lead program is QTORIN 3.9% rapamycin, an investigational topical gel being developed for microcystic lymphatic malformations, rare lesions caused by abnormalities in the lymphatic system.
Featured Articles
- Five stocks we like better than Palvella Therapeutics
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
